公开(公告)号：US20090036680A1

公开(公告)日：2009-02-05

申请号：US10586555

申请日：2005-01-19

Applicant: Yatendra Kumar ,  Mohammad Rafeeq ,  Shantanu De ,  Swargam Sathyanarayana

Inventor： Yatendra Kumar ,  Mohammad Rafeeq ,  Shantanu De ,  Swargam Sathyanarayana

IPC: C07D239/42

CPC classification number: C07D239/42

Abstract: The present invention relates to salts of HMG CoA reductase inhibitors, and in particular, rosuvastatin amine salts and their use as intermediates in the preparation of rosuvastatin calcium.

Abstract translation: 本发明涉及HMG CoA还原酶抑制剂的盐，特别涉及罗苏伐他汀胺盐及其作为制备罗苏伐他汀钙的中间体的用途。

公开(公告)号：US20050222415A1

公开(公告)日：2005-10-06

申请号：US10515361

申请日：2003-05-21

Applicant: Yatendra Kumar ,  Shantanu De ,  Mohammad Rafeeq ,  Hashim Nizar Poovanathil Meeran ,  Swargam Sathyanarayana

Inventor： Yatendra Kumar ,  Shantanu De ,  Mohammad Rafeeq ,  Hashim Nizar Poovanathil Meeran ,  Swargam Sathyanarayana

IPC: C07D239/42

CPC classification number: C07D239/42

Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of 4-4(fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulphonylamino)-5-pyrimidinecarboxaldehyde, referred to here as pyrimidine aldehyde of structural Formula I and to the use of this compound as intermediate for the preparation of rosuvastatin.

Abstract translation: 本发明涉及用于制备4-4（氟苯基）-6-异丙基-2-（N-甲基-N-甲基磺酰基氨基）-5-嘧啶甲醛的成本有效和工业上有利的方法，这里称为嘧啶醛 结构式I和该化合物作为制备罗苏伐他汀的中间体的用途。

公开(公告)号：US20070191318A1

公开(公告)日：2007-08-16

申请号：US10576410

申请日：2004-10-22

Applicant: Yatendra Kumar ,  Mohammad Rafeeq ,  Shantanu De ,  Swargam Sathyanarayana

Inventor： Yatendra Kumar ,  Mohammad Rafeeq ,  Shantanu De ,  Swargam Sathyanarayana

IPC: A61K31/56 ,  A01N45/00

CPC classification number: C07D239/42 ,  A61K31/505

Abstract: The invention relates to processes for the preparation of amorphous rosuvastatin calcium. More particularly, it relates to the preparation of pure amorphous rosuvastain calcium and pharmaceutical compositions that include the pure amorphous rosuvastatin calcium. The invention also relates to use of said compositions for treating hyperlipidemia, hypercholesterolemia, and atherosclerosis. Formula (I).

Abstract translation: 本发明涉及制备无定形罗苏伐他汀钙的方法。 更具体地说，本发明涉及纯无定形罗苏伐他汀钙和包括纯无定形罗苏伐他汀钙的药物组合物的制备。 本发明还涉及所述组合物用于治疗高脂血症，高胆固醇血症和动脉粥样硬化的用途。 式（I）。

公开(公告)号：US07566782B2

公开(公告)日：2009-07-28

申请号：US10537859

申请日：2002-12-10

Applicant: Yatendra Kumar ,  Hashim Nizar Poovanathil Nagoor Meeran ,  Shantanu De ,  Mohammad Rafeeq ,  Swargam Sathyanarayana

Inventor： Yatendra Kumar ,  Hashim Nizar Poovanathil Nagoor Meeran ,  Shantanu De ,  Mohammad Rafeeq ,  Swargam Sathyanarayana

IPC: C07D239/42 ,  C07D403/12 ,  C07D413/12 ,  C07F9/535 ,  C07F7/18 ,  A61K31/505 ,  A61K31/506 ,  A61P3/06 ,  A61P3/10

CPC classification number: C07D239/42 ,  C07F7/1804 ,  C07F9/5352

Abstract: The present invention relates to a process for the preparation of rosuvastatin calcium, a promising new HMG-CoA reductase inhibitor.

Abstract translation: 本发明涉及一种有前景的新型HMG-CoA还原酶抑制剂瑞舒伐他汀钙的制备方法。

公开(公告)号：US20080234302A1

公开(公告)日：2008-09-25

申请号：US11575817

申请日：2005-09-20

Applicant: Mohammad Rafeeq ,  Shantanu De ,  Swargam Sathyanarayana ,  Yatendra Kumar

Inventor： Mohammad Rafeeq ,  Shantanu De ,  Swargam Sathyanarayana ,  Yatendra Kumar

IPC: A61K31/505 ,  C07D239/42 ,  A61P3/06

CPC classification number: C07D239/42

Abstract: Provided are processes for preparing amorphous rosuvastatin calcium from crystalline rosuvastatin calcium by simple precipitation processes. Also provided is a novel polymorphic form of rosuvastatin sodium, processes for preparing thereof and pharmaceutical compositions thereof.

Abstract translation: 提供了通过简单的沉淀方法从结晶瑞舒伐他汀钙制备无定形瑞舒伐他汀钙的方法。 还提供了瑞舒伐他汀钠的新型多晶型物，其制备方法及其药物组合物。

公开(公告)号：US20070244144A1

公开(公告)日：2007-10-18

申请号：US11733594

申请日：2007-04-10

Applicant: Deepak MURPANI ,  Mohammad RAFEEQ ,  Praveen RAHEJA ,  Swargam SATHYANARAYANA ,  Mohan PRASAD

Inventor： Deepak MURPANI ,  Mohammad RAFEEQ ,  Praveen RAHEJA ,  Swargam SATHYANARAYANA ,  Mohan PRASAD

IPC: A61K31/473 ,  C07D221/06

CPC classification number: C07D401/04

Abstract: The present invention relates to an improved process for the preparation of Form 1 of desloratadine essentially free of Form 2. The invention also relates to Form 1 of desloratadine substantially free of Form 2, process for its preparation, pharmaceutical composition comprising it and its method of use for the treatment of allergic reactions in mammals.

Abstract translation: 本发明涉及用于制备基本上不含形式2的地氯雷他定1型的改进方法。本发明还涉及基本上不含形式2的地氯雷他定1型，其制备方法，包含其的药物组合物及其方法 用于治疗哺乳动物过敏反应。